# A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants

> **NCT06619483** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 24 (actual)

## Conditions studied

- Acute Venous and Arterial Thrombotic and Thromboembolic Events
- Healthy Volunteers

## Interventions

- **DRUG:** BAY3018250 Dose 1
- **DRUG:** Placebo
- **DRUG:** BAY3018250 Dose 2

## Key facts

- **NCT ID:** NCT06619483
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-10
- **Primary completion:** 2025-01-24
- **Final completion:** 2025-01-24
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06619483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06619483, "A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06619483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*